Evolus
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 273
- Market Cap
- $1B
- Website
- http://www.evolus.com
- Introduction
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05481931
- Locations
- 🇩🇪
Cologne Dermatology, Cologne, Germany
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: PrabotulinumtoxinA-Xvfs
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT05320393
- Locations
- 🇺🇸
Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida, United States
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
- Conditions
- Glabellar Frown Lines
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 570
- Registration Number
- NCT02428608
- Locations
- 🇺🇸
The Advanced Skin Research Center at Skin Specialists, PC, Omaha, Nebraska, United States
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
- Conditions
- Glabellar Frown Lines
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT02334436
- Locations
- 🇺🇸
The Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
- Conditions
- Glabellar Frown Lines
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02334423
- Locations
- 🇺🇸
Steven Fagien, MD, Boca Raton, Florida, United States
- Prev
- 1
- 2
- Next
News
AEON Biopharma Appoints Rob Bancroft as New CEO to Lead ABP-450 Therapeutic Development
AEON Biopharma has appointed industry veteran Rob Bancroft as Chief Executive Officer to lead the company's development of ABP-450 for therapeutic applications.
FDA Approves Evolus' Novel Hyaluronic Acid Dermal Fillers with Superior Efficacy Profile
Evolus, Inc. receives FDA approval for two new injectable hyaluronic acid dermal fillers, Evolysse Form and Evolysse Smooth, marking their entry into the dermal filler market.